"Rising Demand for Weight-Loss Drugs Drives Syringe-Filling Firms' Success"
Contract drug manufacturers are investing billions of dollars to expand or build factories that fill the injection pens used for weight-loss drugs like Novo Nordisk's Wegovy. The demand for self-injection weight-loss drugs is soaring, with the obesity market estimated to be worth $100 billion within a decade. Pharmaceutical services companies are racing to secure more of the specialist work of filling the syringes used in the pens, known as fill-finish. Companies like WuXi Biologics and Catalent are expanding their pre-filled syringe capacity, while Novo's partner Thermo Fisher is converting facilities to handle pens for obesity and diabetes medicines. The race for business among contract development and manufacturing organizations (CDMOs) is accelerating, driven by the launch of new weight-loss drugs and the increasing demand for injectables.